Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Non-Current Liabilities: 2020-2024

Historic Other Non-Current Liabilities for UroGen Pharma (URGN) over the last 5 years, with Dec 2024 value amounting to $3.8 million.

  • UroGen Pharma's Other Non-Current Liabilities rose 18.69% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 18.69%. This contributed to the annual value of $3.8 million for FY2024, which is 18.69% up from last year.
  • According to the latest figures from FY2024, UroGen Pharma's Other Non-Current Liabilities is $3.8 million, which was up 18.69% from $3.2 million recorded in FY2023.
  • UroGen Pharma's Other Non-Current Liabilities' 5-year high stood at $3.8 million during FY2024, with a 5-year trough of $2.7 million in FY2020.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $3.2 million (2023), whereas its average is $3.3 million.
  • Data for UroGen Pharma's Other Non-Current Liabilities shows a peak YoY increased of 18.69% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows UroGen Pharma's Other Non-Current Liabilities stood at $2.7 million in 2020, then rose by 4.60% to $2.8 million in 2021, then rose by 6.19% to $3.0 million in 2022, then rose by 5.83% to $3.2 million in 2023, then grew by 18.69% to $3.8 million in 2024.